Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
